Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or... – Recovery or purification
Reexamination Certificate
2008-09-02
2008-09-02
Lankford, L Blaine (Department: 1651)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
Recovery or purification
C435S235100, C210S656000, C210S661000, C424S093600
Reexamination Certificate
active
10166347
ABSTRACT:
The present invention provides methods of purifying adeno-associated virus (AAV) particles. These AAV particles include AAV2, AAV4 and AAV5 particles. The present invention also provides AAV particles purified by the methods of the present invention.
REFERENCES:
patent: 6146874 (2000-11-01), Zolotukhin et al.
patent: 6180613 (2001-01-01), Kaplitt et al.
patent: 6221349 (2001-04-01), Couto et al.
patent: 6309634 (2001-10-01), Bankiewicz et al.
patent: 6391858 (2002-05-01), Podsakoff et al.
patent: 6468524 (2002-10-01), Chiorini et al.
patent: 6485976 (2002-11-01), Nadler et al.
patent: 6855314 (2005-02-01), Chiorini et al.
patent: 6984517 (2006-01-01), Chiorini et al.
patent: 2002/0076754 (2002-06-01), Sun et al.
patent: 2003/0228282 (2003-12-01), Gao et al.
patent: 2004/0086490 (2004-05-01), Chiorini et al.
patent: 2004/0115789 (2004-06-01), Meruelo et al.
patent: 2005/0255089 (2005-11-01), Chiorini et al.
patent: 44 36 664 (1996-07-01), None
patent: 1 310 571 (2003-05-01), None
patent: WO 93/24641 (1993-12-01), None
patent: WO 95/11997 (1995-05-01), None
patent: WO 96/00587 (1996-01-01), None
patent: WO 96/15777 (1996-05-01), None
patent: WO 96/18727 (1996-06-01), None
patent: WO 97/06272 (1997-02-01), None
patent: WO 98/11244 (1998-03-01), None
patent: WO 98/41240 (1998-09-01), None
patent: WO 98/45462 (1998-10-01), None
patent: WO 99/61601 (1999-12-01), None
patent: WO 00/26254 (2000-05-01), None
patent: WO 00/28061 (2000-05-01), None
patent: WO 01/70276 (2001-09-01), None
patent: WO 01/83692 (2001-11-01), None
patent: WO 03/093479 (2003-11-01), None
patent: WO 2004/112727 (2004-12-01), None
patent: WO 2005/017101 (2005-02-01), None
patent: WO 2005/056807 (2005-06-01), None
patent: WO 2006/029196 (2006-03-01), None
patent: WO 2006/119432 (2006-11-01), None
Alexander et al., “DNA-Damaging Agents Greatly Increase the Transduction of Nodividing Cells by Adeno-Associated Virus Vectors”J. Virol. 68(12):8282-8287, Dec. 1994.
Alisky et al., “Transduction of Murine Cerebellar Neurons with Recombinant FIV and AAV5 Vectors”Mol. Neurosci. 11(1221):2669-2673, Aug. 2000.
Auricchio et al., “A Single-Step Affinity Column for Purification of Serotype-5 Based Adeno-Associated Viral Vectors”Mol Ther4(4):372-374, Oct. 2001.
Chiorini et al., “Cloning and Characterization of Adeno-Associated Virus Type 5”J. Virol. 73(2):1309-1319, Feb. 1999.
Chiorini et al., “Cloning of Adeno-Associated Virus Type 4 (AAV4) and Generation of Recombinant AAV4 Particles”J. Virol. 71(9):6823-6833, Sep. 1997.
Clark et al., “Highly Purified Recombinant Adeno-Associated Virus Vectors are Biologically Active and Free of Detectable Helper and Wild-Type Viruses”Hum. Gene Ther. 10:1031-1039, Apr. 10, 1999.
Flannery et al., “Efficient Photoreceptor-targeted Gene Expression in vivo by Recombinant Adeno-Associated Virus”Proc Natl Acad Sci U S A94:6916-6921, Jun. 1997.
Kaludov et al., “Adeno-Associated Virus Serotype 4 (AAV4) and AAV5 Both Require Sialic Acid Binding for Hemagglutination and Efficient Transduction but Differ in Sialic Acid Linkage Specificity”J. Virol, 75(15):6884-6893, Aug. 2001.
Kaludov et al., “Scalable Purification of Adeno-Associated Virus Type 2, 4 or 5 Using Ion-Exchange Chromatography”Human Gene Therapy 13:1235-1243, Jul. 2002.
Kaplitt et al. “Long Term Gene Expression and Phenotypic Correction using Adeno-Associated Virus Vectors in the Mammalian Brain”Nat. Gen. 8:148-154, Oct. 1994.
McCown et al., “Differential and Persistent Expression Patterns of CNS Gene Transfer by an Adeno-Associated Virus (AAV) Vector”Brain Res 713:99-107 (1996).
O'Riordan et al., “Scalable Chromatographic Purification Process for Recombinant Adeno-Associated Virus (rAAV)”J Gene Med 2:444-454 (2000).
Russell et al., “Adeno-Associated Virus Vectors Preferentially Transduce Cells in S Phase”Proc. Natl. Acad. Sci. USA 91: 8915-8919, Sep. 1994.
Rutledge et al., “Infectious Clones and Vectors Derived Form Adeno-Associated Virus (AAV) Serotypes other Than AAV Type 2”J. Virol. 72:309-319, Jan. 1998.
Snyder et al., “Persistent and Therapeutic Concentrations of Human Factor IX in Mice after Hepatic Gene transfer of Recombinant AAV Vectors”Nat Genet 16:270-276, Jul. 1997.
Xiao et al., “Efficient Long-Term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Adeno-Associated Virus Vector”J. Virol. 70(11):8098-8108, Nov. 1996.
Zolotukhin et al., “Recombinant Adeno-Associated Virus Purification using Novel Methods Improves Infections Titer and Yield”Gene Ther. 6: 973-985 (1999).
Alisky J.M. and Tolbert D.M., “Differential labeling of converging afferent pathways using biotinylated dextran amine and cholera toxin subunit B,” 1994,Journal of Neuroscience Methods, 52:143-148.
Allen, J.M., Halbert, C.L. and Miller, A.D., “Improved adeno-associated virus vector production with transfection of a single helper adenovirus gene, E4orf6,” 2000,Mol Ther, 1:88-95.
Arnberg, N., A. H. Kidd, K. Edlund, J. Nilsson, P. Pring-Akerblom, and G. Wadell, “Adenovirus type 37 binds to cell surface sialic acid through a charge-dependent interaction,” 2002,Virology, 302:33-43.
Atchison, R. W., B. C. Casto, and W. M. Hammon, “Adenovirus-Associated Defective Virus Particles,” 1965,Science, 149:754-756.
Bachmann, P.A., M.D. Hoggan, E. Kurstak, J.L. Melnick, H.G. Pereira, P. Tattersall, and C. Vago, “Parvoviridae: second report,”1979,Interverology, 11:248-254.
Bajocchi G, Feldman SH, Crystal RG, Mastrangeli A., “Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors,” 1993,Nat Genet, 3:229-234.
Bantel-Schaal U, Delius H, Schmidt R, zur Hausen H., “Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses,” 1999,J Virol., 73(2):939-947.
Bantel-Schaal U, zur Hausen H., “Characterization of the DNA of a defective human parvovirus isolated from a genital site,” 1984,Virology, 134(1):52-63, XP009028974.
Bantel-Schaal, U. and M. Stohr, “Influence of adeno-associated virus on adherence and growth properties of normal cells,” 1992,J. Virol., 66:773-779.
Bantel-Schaal, U., Hub, B. and Kartenbeck, J., “Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment,”2002,J Virol, 76:2340-2349.
Bartlett JS, Kleinschmidt J., Boucher RC, and Samulski RJ, “Targeted adeno-associated virus vector transduction of nonpermissive cell mediated by a bispecific F(ab'gamma)2antibody,” 1999,Nat Biotechnol, 17:181-186.
Bartlett JS, Samulski RJ, McCown TJ., “Selective and rapid uptake of adeno-associated virus type 2 in brain,” 1998,Hum Gene Ther, 9(8):1181-1186.
Bartlett, J.S., Wilcher, R. and Samulski, R.J., “Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors,” 2000,J Virol, 74:2777-2785.
Ben-Israel, H. and Kleinberger, T., “Adenovirus and cell cycle control,” 2002,Front Biosci, 7:d1369-1395.
Bergelson, JM, Cunningham JA, Droguett G., Kurt-Jones EA, Krithivas A., Hong JS, Horwitz MS, Crowell RL, and Finberg RW, “Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5,” 1997,Science, 275:1320-1323.
Berns, K. I., “Parvoviridae: the viruses and their replication,”InF. B. N., K. D. M., and H. P. M. (ed.),Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA, p. 2173-2197, date unknown.
Blacklow, et al., “Serologic Evidence for Human Infection With Adenovirus-Associated Viruses,” 1968,J NCI, 40(2):319-327.
Blacklow, N.R., Hoggan, M.D. and Rowe, W.P. “Isolation of adenovirus-associated viruses from man,” 1967,Proc Natl Acad Sci U S A, 58:1410-1415.
Bomsel M. Alfsen A, ȁ
Chiorini John A.
Kaludov Nikola A.
Lankford L Blaine
Needle & Rosenberg P.C.
The United States of America as represented by the Secretary Dep
LandOfFree
Scalable purification of AAV2, AAV4 or AAV5 using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Scalable purification of AAV2, AAV4 or AAV5 using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Scalable purification of AAV2, AAV4 or AAV5 using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3950243